<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> are more likely than the general population to develop <z:mp ids='MP_0002055'>diabetes</z:mp>, which contributes to a high risk of cardiovascular complications; individuals with <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> are two to three times more likely to die from <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> than the general population </plain></SENT>
<SENT sid="1" pm="."><plain>The risk of <z:mp ids='MP_0002055'>diabetes</z:mp>, and hence <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, is particularly increased by some of the new atypical antipsychotic drugs </plain></SENT>
<SENT sid="2" pm="."><plain>Individuals taking an atypical <z:chebi fb="0" ids="35476">antipsychotic drug</z:chebi>, particularly younger patients under 40 years of age (odds ratio 1.63, 95% CI 1.23-2.16), represent an underrecognized group at high risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanisms responsible for antipsychotic-induced <z:mp ids='MP_0002055'>diabetes</z:mp> remain unclear </plain></SENT>
<SENT sid="4" pm="."><plain>Hypotheses include these drugs' potential to cause <z:mp ids='MP_0005456'>weight gain</z:mp>, possibly through antagonism at the H(1), <z:chebi fb="0" ids="28790">5-HT</z:chebi>(2A), or <z:chebi fb="0" ids="28790">5-HT</z:chebi>(2C) receptors </plain></SENT>
<SENT sid="5" pm="."><plain>Other mechanisms independent of <z:mp ids='MP_0005456'>weight gain</z:mp> lead to elevation of serum leptin and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychoses</z:e> have difficulties with diet and lifestyle interventions for <z:mp ids='MP_0002055'>diabetes</z:mp> and weight management </plain></SENT>
<SENT sid="7" pm="."><plain>If <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> develops, withdrawal from antipsychotic medication will often be inappropriate, and a change to an atypical <z:chebi fb="0" ids="35476">antipsychotic drug</z:chebi> with lower diabetogenic potential should be considered, especially in younger patients </plain></SENT>
<SENT sid="8" pm="."><plain>Management of <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychoses</z:e> should routinely include body weight and blood <z:chebi fb="105" ids="17234">glucose</z:chebi> monitoring and steps to promote exercise and minimize <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Careful collaboration between the psychiatric and diabetology teams is essential to minimize the risk of <z:mp ids='MP_0002055'>diabetes</z:mp> in patients taking atypical antipsychotic medication and for effective management when it develops </plain></SENT>
<SENT sid="10" pm="."><plain>This collaboration will also help minimize the already high risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in individuals with <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> </plain></SENT>
</text></document>